Pharmacyclics has acquired multiple small molecule drug candidates for the treatment of cancer and other diseases from Celera Genomics. The deal includes technology and intellectual property relating to drugs that target histone deacetylase (HDAC) enzymes, selective HDAC enzymes, angiogenesis molecules and B cell tyrosine kinases involved in immune function. Pharmacyclics made an upfront cash payment of $2 million and an equity payment of between five hundred thousand and one million shares o...